Erectile dysfunction among testicular cancer survivors: A systematic review and meta-analysis

Abstract

Background: Erectile dysfunction is one of the common complications of testicular cancer with the prevalence of 11.3% to 84%. It has devastating effects on men and partner's quality of life, sexual satisfaction, and sexual experience. The findings of the previous studies on this matter were uneven and inconsistent. Therefore, this systematic review and meta-analysis is conducted in order to acquire a more recent and comprehensive result. Methods and materials:To search and retained all the eligible articles different databases were searched. These includes PubMed, Scopus, Goggle scholar, Science Direct, African Index Medicus, African Journal online, EMBASE, and Cochrane Library. To extract all the relevant information, a standardized data extraction checklist was prepared. STATA 14 statistical software was utilized to analyze the data. I 2 statistics was employed to check for the heterogeneity of studies.Using a funnel plot and Egger's regression test publication bias was checked. Then, a randomeffect model was computed to estimate the pooled prevalence of erectile dysfunction.Result: Fourteen full-text studies were included in this systematic review and meta-analysis. The pooled prevalence of erectile dysfunction among testicular cancer survivors was found to be 34.60% (95% CI: 25. 89, 43.30% [I 2 = 95.9%, p = 0.000]). Study design subgroup analysis indicated that the pooled prevalence of erectile dysfunction was 50.02% (95% CI: 22.78, 77.28% [I 2 = 96.1, p = 0.000]) and 27.36. % (95% CI: 19.23, 34.48% [I 2 = 91.6, P = 0.000]) in the case control and cohort studies respectively. Likewise, the level of erectile dysfunction was varied based on erectile dysfunction measuring tools and testicular cancer treatment modalities. Conclusion:The pooled prevalence of erectile dysfunction in testicular cancer survivors was found to be high. It had also a considerable discrepancy between the study designs, and measuring tools and treatment modalities of testicular cancer. Therefore, there is a sound to diminish the high burden of this problem.

Testicular Cancer Treatments and Sexuality: A Narrative Review

“…This result is in line with other studies reporting alteration of ejaculation [10,67]; van Basten analyzed 43 patients treated with a systemic treatment and showed that 17.4% exhibited a decreased semen amount and 18.7% exhibited a complete absence of antegrade ejaculation [10]. A decreased erection potential was also found in patients treated with chemotherapy [36,43,[67][68][69]. In 2018, Bandak et al demonstrated that the risk of erectile dysfunction in 2260 long-term survivors of testicular cancer compared to surveillance was significantly higher [68].…”

Ultrasound-based deep learning radiomics nomogram for risk stratification of testicular masses: a two-center study

“…For patients with benign testicular tumors, partial orchiectomy can conserve testicular function (Fankhauser et al 2021 ; Paffenholz et al 2018 ; Gentile et al 2020 ; Sm et al 2023 ). Conversely, unneeded surgical resections for those with non-neoplastic testicular lesions can adversely affect androgen levels, sexual function, fertility, among others (Henriques et al 2022 ; Kerie et al 2021 ). Hence, it’s paramount to study and ascertain the nature of testicular masses to minimize unnecessary surgeries and reduce missed diagnoses of malignancies.…”

“…However, testicular malignancies often require radical orchiectomy. Studies have shown that unilateral orchiectomy can result in infertility, sexual dysfunction, and reduced sexual function (Henriques et al 2022 ; Kerie et al 2021 ). Recently, some studies suggest that benign testicular tumors smaller than 2–3 cm in diameter can have a favorable prognosis with partial orchiectomy and adjuvant radiotherapy (Fankhauser et al 2021 ; Paffenholz et al 2018 ; Gentile et al 2020 ; Sm et al 2023 ).…”

Unilateral Post-Chemotherapy Robot-Assisted Retroperitoneal Lymph Node Dissection for Stage II Non-Seminomatous Germ Cell Tumors: Sexual and Reproductive Outcomes

“…Nevertheless, significant impairments in orgasmic function, intercourse, and overall sexual satisfaction were observed following RPLND. In our cohort, more than one in three testicular cancer survivors can experience ED, with higher prevalence rates among those who require more than one treatment modality (radiation, surgery, and chemotherapy) [ 25 ]. However, only a few published data explore the prevalence of new-onset ED in men who underwent RPLND.…”